Im, Seock-Ah
Xu, Binghe
Li, Wei
Robson, Mark
Ouyang, Quchang
Yeh, Dah-Cherng
Iwata, Hiroji
Park, Yeon Hee
Sohn, Joo Hyuk
Tseng, Ling-Ming
Goessl, Carsten
Wu, Wenting
Masuda, Norikazu http://orcid.org/0000-0002-7302-0278
Funding for this research was provided by:
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).
This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD).
Article History
Received: 31 July 2019
Accepted: 17 January 2020
First Online: 29 May 2020
Competing interests
: S-AI has acted in a consulting or advisory role for AstraZeneca, Hanmi Pharmaceutical, Novartis, Roche, Pfizer and Spectrum, and received research funding from AstraZeneca; MR has acted in a consulting role for AstraZeneca and McKesson and received honoraria from AstraZeneca, and research funding from AstraZeneca, AbbVie, Myriad Genetics and Medivation; H.I. has received honorarium from AstraZeneca, Chugai, Eisai, Pfizer, Daiichi-Sankyo, Novartis, Lilly and research funding from AstraZeneca, Bayer, Chugai, Daiichi-Sankyo, Kyowa Hakko Kirin, Lilly, MSD, Novartis and Pfizer; N.M. has received research funding from AstraZeneca, Chugai, Eli-Lily, Kyowa-Kirin, MSD, Novartis and Pfizer and honoraria from AstraZeneca, Chugai and Kyowa-Kirin; C.G. and W.W. are employees of AstraZeneca; B.X., Q.O., D.-C.Y., J.H.S., L.-M.T., W.L. and Y.H.P. declare no conflict of interest.